Based on these results, T-DXd was FDA-approved in 2022 for patients with HER2-positive gastric or GEJ adenocarcinomas who had received prior trastuzumab [115]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.